Synairgen’s inhaled COVID-19 treatment included in US trial
Synairgen’s inhaled interferon beta-1a treatment, SNG001, has been selected for inclusion in the US government-funded ACTIV-2 trial in COVID-19 outpatients.
The Ph...
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingExploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingExploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingHighlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement